141 related articles for article (PubMed ID: 22664479)
1. A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.
Han JY; Shin ES; Lee YS; Ghang HY; Kim SY; Hwang JA; Kim JY; Lee JS
Pharmacogenomics J; 2013 Oct; 13(5):417-22. PubMed ID: 22664479
[TBL] [Abstract][Full Text] [Related]
2. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
3. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Kim HT; Lee JS
Lung Cancer; 2008 Jan; 59(1):69-75. PubMed ID: 17766002
[TBL] [Abstract][Full Text] [Related]
4. Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.
Takahashi H; Sai K; Saito Y; Kaniwa N; Matsumura Y; Hamaguchi T; Shimada Y; Ohtsu A; Yoshino T; Doi T; Okuda H; Ichinohe R; Takahashi A; Doi A; Odaka Y; Okuyama M; Saijo N; Sawada J; Sakamoto H; Yoshida T
PLoS One; 2014; 9(8):e105160. PubMed ID: 25127363
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703.
Matsubara N; Maemondo M; Inoue A; Ishimoto O; Watanabe K; Sakakibara T; Fukuhara T; Morikawa N; Tanaka M; Sugawara S; Nukiwa T
Respir Investig; 2013 Mar; 51(1):28-34. PubMed ID: 23561256
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
Adjei AA; Argiris A; Murren JR
Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Kweekel D; Guchelaar HJ; Gelderblom H
Cancer Treat Rev; 2008 Nov; 34(7):656-69. PubMed ID: 18558463
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
10. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
Chang MH; Kim KH; Jun HJ; Kim HS; Yi SY; Uhm JE; Park MJ; Lim DH; Ji SH; Hwang IG; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
Cancer Chemother Pharmacol; 2009 Oct; 64(5):917-24. PubMed ID: 19221753
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between UGT1A and irinotecan-related toxicity].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249
[No Abstract] [Full Text] [Related]
13. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
Mori K; Kondo T; Kamiyama Y; Kano Y; Tominaga K
Cancer Chemother Pharmacol; 2003 May; 51(5):403-6. PubMed ID: 12687289
[TBL] [Abstract][Full Text] [Related]
14. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Park YH; Lee SY; Lee JS
Lung Cancer; 2009 Jan; 63(1):115-20. PubMed ID: 18221820
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
Read W; McLeod H; Govindan R
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):15-7. PubMed ID: 15685828
[TBL] [Abstract][Full Text] [Related]
16. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan in cancers of the lung and cervix.
Sandler A; van Oosterom AT
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S13-7. PubMed ID: 10630363
[TBL] [Abstract][Full Text] [Related]
18. A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.
Han JY; Lee YS; Shin ES; Hwang JA; Nam S; Hong SH; Ghang HY; Kim JY; Yoon SJ; Lee JS
Pharmacogenomics J; 2014 Feb; 14(1):20-7. PubMed ID: 23478653
[TBL] [Abstract][Full Text] [Related]
19. Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.
Han JY; Lee GK; Yoo SY; Yoon SJ; Cho EY; Kim HT; Lee JS
Pharmacogenomics J; 2010 Apr; 10(2):86-93. PubMed ID: 19859084
[TBL] [Abstract][Full Text] [Related]
20. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
